International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationComparative Effectiveness of 5 Treatment Strategies for Early-Stage Non-Small Cell Lung Cancer in the Elderly
Introduction
Although advanced non-small cell lung cancer is associated with poor prognosis, early-stage presentations are potentially curable, with 5-year rates of overall survival (OS) approaching 50% (1). In the United States, 2 public health developments will increase the burden of early lung cancer and strain limited health care dollars. First, the overall incidence of NSCLC among adults over 65 is expected to rise dramatically from a level of 163,000 in 2010 to 271,000 by 2030 because of the demographic changes associated with population aging (2). Second, recent evidence showing a mortality benefit from computed tomography screening may lead to a rise in newly diagnosed early-stage (T1a-T2a N0) lung cancers as screening disseminates into routine care (3).
Patients with NSCLC are frequently older and experience a high burden of comorbid illness. Surgical resection for early-stage disease affords a high likelihood of cure but is often precluded by comorbid illness that renders patients medically inoperable. New minimally invasive methods for thoracic surgery and a novel radiation therapy modality, stereotactic ablative radiation therapy (SABR), promise to improve outcomes in elderly patients who previously would not have been candidates for curative surgical therapy. However, no phase 3 randomized data are available to guide integration of these newer therapies into treatment selection for the elderly.
Given the urgency of this health policy question and the lack of randomized data to guide therapy, we used the Surveillance, Epidemiology, and End Results (SEER)-Medicare cohort to identify patients older than 65 treated for early-stage NSCLC between 2001 and 2007, during which time all major contemporary treatment strategies were in use. We sought to determine the comparative effectiveness of lobectomy, sublobar resection, conventional radiation, SABR, and observation with respect to OS and lung cancer-specific survival (LCSS).
Section snippets
Data source
The Surveillance, Epidemiology, and End Results (SEER)-Medicare database captures clinical, pathologic, and insurance claims data for incident cancers diagnosed in Medicare beneficiaries who reside within 1 of 16 geographic catchment areas that account for 26% of the United States population. The case ascertainment rate for the SEER data is approximately 98% (4). In this study, demographic and tumor characteristics for incident malignancies diagnosed from January 1, 2001, to December 31, 2007,
Baseline characteristics and unadjusted outcomes
Among the 10,923 patients, the median age was 75 years, 54.1% were female, and 29% had moderate to severe comorbidity. The treatment strategy was as follows: 6531 lobectomy (58.9%), 1277 sublobar resection (11.7%), 1613 conventional radiation (14.8%), 1378 supportive care (12.6%), and 124 SABR (1.1%). Nodal sampling to establish pathologic node-negative status was accomplished in 94% of the lobectomy patients, 42% of the sublobar resection patients, and fewer than 10% of the nonsurgical
Discussion
The median age of patients with NSCLC is 70 years (10), and the most prevalent risk factor is chronic smoking, which is associated with many systemic medical conditions including chronic obstructive pulmonary disease and coronary artery disease. This combination of advanced age and comorbid illness poses therapeutic challenges and increases the morbidity and mortality risks of treatment. In the absence of randomized data, clinical decision making for the rising number of elderly patients can be
Acknowledgment
The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database.
References (20)
- et al.
Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: an example from the Mayo Lung Project
Lung Cancer
(2009) - et al.
Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives
J Clin Epidemiol
(1993) - et al.
Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database
Chest
(2005) - et al.
Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer
J Thorac Cardiovasc Surg
(2010) - et al.
Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer
Chest
(2005) - et al.
A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies
J Clin Epidemiol
(2010) - et al.
The revised TNM staging system for lung cancer
Ann Thorac Cardiovasc Surg
(2009) - et al.
Future of cancer incidence in the United States: burdens upon an aging, changing nation
J Clin Oncol
(2009) - et al.
Reduced lung-cancer mortality with low-dose computed tomographic screening
N Engl J Med
(2011) - et al.
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population
Med Care
(2002)
Cited by (233)
Microwave Ablation for Inoperable Stage I Non–Small Cell Lung Cancer in Patients Aged ≥70 Years: A Prospective, Single-Center Study
2023, Journal of Vascular and Interventional RadiologyModeling the COVID Pandemic: Do Delays in Surgery Justify Using SBRT to Treat Low-Risk Early Stage NSCLC?
2023, Journal of Surgical ResearchStereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study
2022, International Journal of Radiation Oncology Biology PhysicsAdvances in Imaging to Aid Segmentectomy for Lung Cancer
2022, Surgical Oncology Clinics of North America
Supported by grants from the Cancer Prevention & Research Institute of Texas [Grant RP101207] and the Department of Health and Human Services National Cancer Institute [Grants CA16672, T32CA77050] to Dr Smith.
A portion of this study was funded by a research grant from Varian Medical Systems (SR2011-00034954RG 01). This entity had no role in the study design, data analysis, or data interpretation. Dr Welsh reports a compensated consultory role to Reflexion Medical.